|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical impact of trabeetedin (ecteinascidin -743 ) in advanced/metastatic soft tissue sarcoma显示文摘 | Schǒffski P Dumez H Wolter P | 2008 | Expert Opin Pharmacother2008，9，9： | 1 |
| 2 | Clinacal and pharmacokinetic phase Ⅰ study of multi-targeted antifolate (LY231514) in combination with cisplatin 显示文摘 | Depenbrck H Dumez H | 1999 | J Clin Oncol1999，17，10： | 1 |
| 3 | Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide,a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumors显示文摘 | Eskens FA Dumez H Hoekstra R | 2003 | Eur J Canceer2003，39，7： | 1 |
| 4 | Phase Ⅰ and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974),a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours显示文摘 | ESKENS FA DUMEZ H HOEKSTRA R | 2003 | Eur J Cancer2003，39，7： | 1 |
| 5 | Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase Ⅰ and Ⅱ studies of the EORTC Soft Tissue and Bone Sarcoma Group显示文摘 | Debiec-Rychter M Dumez H Judson I | 2004 | Eur J Cancer2004，40，5： | 1 |
| 6 | The impact of drug administration sequence and pharmacokinetic inter action in a phase Ⅰ study of the combination of docetax el and gemcitabine in patients with advanced solid tumors 显示文摘 | Louwerens M Pawinsky A | 2002 | Anticancer Drugs2002，13，6： | 1 |
| 7 | Phase I and Pharmacologic Study of PK1166,an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,in Patients with Advanced Solid Malignancie显示文摘 | Hoekstra R Dumez H Eskens F A | 2005 | Clin Cancer Res2005，11，19： | 1 |
| 8 | Phase I and pharmacokinet- ic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974),a novel inhibitor of the integrins al- phavbeta3 and alphavbeta5 in patients with advanced solid tu- mours显示文摘 | Eskens FA Dumez H Hoekstra R | 2003 | Eur J Cancer2003，39，7： | 1 |
| 9 | Use of c-kit/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal turnouts entered on phase Ⅰ and Ⅱ studies of the EORTC Soft Tissue and Bone Sarcoma Group显示文摘 | DEBIEC-RYCHTER M DUMEZ H JUDSON I | 2004 | Eur J Cancer2004，40，5： | 1 |
| 10 | Pharmacologic study of PKI-166, an epidermal growth factor recap receptor tyrosine kinase inhibitor, inpatients with advanced solid malignancies显示文摘 | Floekstra R Dumez H Eskens FA | 2005 | Clin Cancer Res2005，11，19： | 1 |
| 11 | Phase I/II pharmaeoki- netic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer显示文摘 | Paridaens R Dirix L Dumez H | 2007 | Clin Breast Cancer2007，7，11： | 1 |
| 12 | Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours显示文摘 | De Jonge MJ Dumez H Kitzen JE | | 0，，09： | 1 |
| 13 | Doeetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer显示文摘 | STERNBERG CN DUMEZ H POPPEL HV | 2009 | Ann One012009，20，7： | 1 |
| 14 | Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin 显示文摘 | DEPENBROCK H DUMEZ | 1999 | J Clin Oncol1999，17，10： | 1 |
| 15 | Phase Ⅰ and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies 显示文摘 | Hoekstra R Dumez H Eskens FALM | 2005 | Clin Cancer Res2005，11，： | 1 |
| 16 | Phase Ⅰ/11 pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer显示文摘 | Paridaens R Dirix L Dumez H | | 0，，11： | 1 |
| 17 | Phase Ⅰ and pharmacokinetie study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974),a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours显示文摘 | Eskens FA Dumez H Hoekstra R | 2003 | Eur J Cancer2003，39，7： | 1 |
| 18 | Phase I, open- label, multicentre, dose-esealation, pharmaeokinetie and pharmacodynamie trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours显示文摘 | SCHOFFSKI P JONES SF DUMEZ H | 2011 | Eur J Cancer2011，47，15： | 1 |
| 19 | Clinical and pharmacokinetic phase Ⅰ study of multitargeted antifolate (LY231514) in combination with cisplatin显示文摘 | Thodtmann R Depenbrock H Dumez H | 1999 | J Clin Oncol1999，17，10： | 1 |
| 20 | Use of c -kit/ PDGFRA mutational analysis to predict the clini- cal response to imatinib in patients with advanced gastro- intestinal stromal tumours entered on phase I and II stud- ies of the EORTC Soft Tissue and Bone Sarcoma Group 显示文摘 | Debiec - Rychter M Dumez H Judson I | 2004 | Cur J Cancer2004，40，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员